Check out the presentation materials and recap of October 27 briefing here.
Outcomes-based contracts and other value-based arrangements (“VBAs”) between pharmaceutical manufacturers and health care payers have become a “tool in the payment toolbox.” VBAs are being employed by payers in Massachusetts and elsewhere to negotiate payments for highly novel pharmaceuticals such as gene therapies, but payers and manufacturers throughout the country are experimenting with VBAs for chronic disease medications as well.
What are the implications for Massachusetts? NEHI’s October 27th briefing will review the status of VBAs in Massachusetts and elsewhere, and lessons learned that may prove useful when Massachusetts state government resumes deliberation on pharmaceutical pricing and payment, largely suspended since the COVID-19 outbreak.
Read more about our incredible panelists here.